Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 6/20 | 0.34 |
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16214027 | 1.00 | CYP4F2 (0.39) | CYP4F2CYP4A11POLBGAANPSR1 | |
| SCHEMBL16214029 | 1.00 | CYP4F2 (0.39) | CYP4F2CYP4A11POLBGAANPSR1 | |
| SCHEMBL16213989 | 1.00 | CYP4F2 (0.39) | CYP4F2CYP4A11POLBGAANPSR1 | |
| SCHEMBL16213998 | 0.93 | POLB (0.37) | CYP4F2CYP4A11POLBGAANPSR1 | |
| SCHEMBL16214032 | 0.85 | CYP4F2 (0.41) | CYP4F2CYP4A11POLBGAANPSR1 | |
| SCHEMBL16214042 | 0.85 | CYP4F2 (0.41) | CYP4F2CYP4A11POLBGAANPSR1 | |
| SCHEMBL16214043 | 0.85 | CYP4F2 (0.41) | CYP4F2CYP4A11POLBGAANPSR1 | |
| SCHEMBL16214026 | 0.85 | CYP4F2 (0.41) | CYP4F2CYP4A11POLBGAANPSR1 | |
| SCHEMBL16214033 | 0.85 | CYP4F2 (0.41) | CYP4F2CYP4A11POLBGAANPSR1 | |
| SCHEMBL16213959 | 0.85 | POLB (0.39) | CYP4F2CYP4A11POLBGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877960-B2 | Fluoroalkanesulfonic acid ammonium salts and method for producing same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2014-11-04 | — | — | US | disclosed |
| US-20110313190-A1 | Fluoroalkanesulfonic Acid Ammonium Salts and Method for Producing Same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313190-A1 | Fluoroalkanesulfonic Acid Ammonium Salts and Method for Producing Same | PFAS, ARSA, NOTUM | CYP4F2 1273/4885CYP4A11 1551/4885POLB 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.